Structural Formula (41d7651e B91a 4118 8719 Bf2f663d82a2 01)
Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 50090-3537
12 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 50090-3537). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (41d7651e B91a 4118 8719 Bf2f663d82a2 02)
A line graph showing ADAS-cog change from baseline over 30 weeks of drug treatment, comparing donepezil hydrochloride 5 mg/day, 10 mg/day, and placebo. The vertical axis represents change in ADAS-cog score, with clinical improvement above baseline and clinical decline below. Donepezil groups show clinical improvement, while placebo exhibits clinical decline over time.*
Figure 2 (41d7651e B91a 4118 8719 Bf2f663d82a2 03)
A line graph showing cumulative percentage of patients versus change from baseline in ADAS-cog scores for three groups: Donepezil hydrochloride 5 mg/day, Donepezil hydrochloride 10 mg/day, and Placebo. The graph displays points indicating 7 points, 4 points improvement, and no change, with the treatment groups showing varied performance over time as annotated.*
Figure 3 (41d7651e B91a 4118 8719 Bf2f663d82a2 04)
A bar chart comparing the percentage of patients with various CIBIC-plus ratings for donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo groups. Ratings range from markedly improved to markedly worse, showing distributions of patient responses across treatment and placebo groups.*
Figure 4 (41d7651e B91a 4118 8719 Bf2f663d82a2 05)
Line chart depicting ADAS-cog mean change from baseline with standard error bars over 15 weeks in three groups: donepezil hydrochloride 10 mg/day, donepezil hydrochloride 5 mg/day, and placebo. The x-axis shows weeks of drug treatment, and the y-axis reflects cognitive change, with clinical improvement above baseline and clinical decline below baseline. Data illustrate changes during active treatment and placebo phases.*
Figure 5 (41d7651e B91a 4118 8719 Bf2f663d82a2 06)
A line graph showing the cumulative percentage of patients versus change from baseline in ADAS-cog scores over time for donepezil hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The graph depicts improvements and no change points with corresponding treatment group data percentages for cognitive change.*
Figure 6 (41d7651e B91a 4118 8719 Bf2f663d82a2 07)
A bar chart showing the percentage of patients by CIBIC-plus rating categories, comparing Aricept 10 mg/day, Aricept 5 mg/day, and placebo groups. The x-axis lists the ratings from markedly improved to markedly worse, and the y-axis shows the percentage of patients from 0 to 50%.*
Figure 7 (41d7651e B91a 4118 8719 Bf2f663d82a2 08)
A line graph showing the change in SIB (Severe Impairment Battery) score from baseline over 6 months of drug treatment. The x-axis represents months of drug treatment at 0, 3, and 6 months. The y-axis shows change from baseline, ranging from -8 to +8. Two lines compare Donepezil hydrochloride 10 mg/day and placebo, with Donepezil showing clinical improvement and placebo showing clinical decline over time.*
Figure 8 (41d7651e B91a 4118 8719 Bf2f663d82a2 09)
A cumulative percentage of patients plot comparing donepezil hydrochloride 10 mg/day with placebo. The X-axis represents SIB change from baseline, ranging from 30 to -75, and the Y-axis shows cumulative percentage of patients from 0% to 100%. The graph has two curves: one with filled circles for donepezil hydrochloride and one with open squares for placebo.*
Figure 9 (41d7651e B91a 4118 8719 Bf2f663d82a2 10)
A line graph depicting the mean change from baseline in ADCS-ADL scores over six months of drug treatment. The graph compares donepezil hydrochloride 10 mg/day and placebo groups, showing greater clinical decline in the placebo group relative to the donepezil group. The y-axis is labeled Change from Baseline (Mean ± SE) and the x-axis represents months of drug treatment (0, 3, 6).*
Figure 10 (41d7651e B91a 4118 8719 Bf2f663d82a2 11)
A line graph showing the cumulative percentage of patients on the vertical axis and the ADCS-ADL change from baseline on the horizontal axis. Two lines compare Donepezil hydrochloride 10 mg/day to placebo, illustrating differences in patient outcomes over a range of ADCS-ADL changes.*
Label Image (Lbl500903537)
donepezil hydrochloride 5 mg film-coated tablets, oral dosage form by A-S Medication Solutions. The label shows product NDC 50090-3537-0, lot information, and storage conditions between 59 to 86 degrees Fahrenheit. The package contains 90 tablets.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
